{ "instance": { "pear-20211223.htm": { "axisCustom": 4, "axisStandard": 42, "contextCount": 629, "dts": { "calculationLink": { "local": [ "pear-20211223_cal.xml" ] }, "definitionLink": { "local": [ "pear-20211223_def.xml" ] }, "inline": { "local": [ "pear-20211223.htm" ] }, "labelLink": { "local": [ "pear-20211223_lab.xml" ] }, "presentationLink": { "local": [ "pear-20211223_pre.xml" ] }, "schema": { "local": [ "pear-20211223.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 816, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://xbrl.sec.gov/dei/2021": 2, "total": 4 }, "keyCustom": 113, "keyStandard": 470, "memberCustom": 79, "memberStandard": 59, "nsprefix": "pear", "nsuri": "http://www.peartherapeutics.com/20211223", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.peartherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1009010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i90e2a9731bd94ae7914bac3c04922c9e_I20210930", "decimals": "0", "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie6f22a97f15147eeb1eb1587edd47e78_D20210202-20210202", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2477443 - Disclosure - Private Placement - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "shortName": "Private Placement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ic321105f99764c599f402171299fea3f_D20210204-20210204", "decimals": "INF", "lang": "en-US", "name": "pear:ClassOfWarrantsOrRightsNumberOfWarrantsIssuedDuringThePeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i3c11aa8dc6f940b09a2993ef44a46946_I20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2480444 - Disclosure - Related Party Transactions - Schedule Of Quantitative Information Regarding Fair Value Measurements of Promissory Note (Detail)", "role": "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail", "shortName": "Related Party Transactions - Schedule Of Quantitative Information Regarding Fair Value Measurements of Promissory Note (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i760eb01137a64536b999a31d0c2474e6_I20210930", "decimals": "1", "lang": "en-US", "name": "us-gaap:DebtInstrumentMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "d", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481445 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i2e5fbd6f6665444f925c8c7112c618fd_I20201231", "decimals": "0", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "if77f42c9d4af45e8900d9952b831f534_I20210204", "decimals": "2", "first": true, "lang": "en-US", "name": "pear:DeferredUnderwritingCommissionPerUnit", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483446 - Disclosure - Commitments - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "shortName": "Commitments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "if77f42c9d4af45e8900d9952b831f534_I20210204", "decimals": "2", "first": true, "lang": "en-US", "name": "pear:DeferredUnderwritingCommissionPerUnit", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2485447 - Disclosure - Stockholder's Equity - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "shortName": "Stockholder's Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i3878ddce0b964f509745ab3a8b08b760_I20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i2e5fbd6f6665444f925c8c7112c618fd_I20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2487448 - Disclosure - Warrants - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail", "shortName": "Warrants - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i4e5e4fc7220d431e9f4ca4cc4ce07ddb_I20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2490449 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)", "role": "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "shortName": "Fair Value Measurements - Summary of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i4e5e4fc7220d431e9f4ca4cc4ce07ddb_I20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i90e2a9731bd94ae7914bac3c04922c9e_I20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2491450 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iffcca3b6623c4ab7b7725824ad60163d_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ProceedsFromInterestReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ia43d12d6e0cf4e1bb71acb120a4bffe8_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2492451 - Disclosure - Fair Value Measurements - Schedule Of Quantitative Information Regarding Level 3 Fair Value Measurements (Detail)", "role": "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "shortName": "Fair Value Measurements - Schedule Of Quantitative Information Regarding Level 3 Fair Value Measurements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ia43d12d6e0cf4e1bb71acb120a4bffe8_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iaa53c5cbff204e87ac685b91a92c0edf_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2493452 - Disclosure - Fair Value Measurements - Summary of Changes in the Fair Value of Warrant Liabilities (Detail)", "role": "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "shortName": "Fair Value Measurements - Summary of Changes in the Fair Value of Warrant Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iac857d5a599a48dca534d9b5fb1911ba_D20210101-20210630", "decimals": "0", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1010011 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:TemporaryEquityRedemptionPricePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i3c44a43750184883a233d68c335821f2_I20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:TemporaryEquityRedemptionPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie6f22a97f15147eeb1eb1587edd47e78_D20210202-20210202", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2495453 - Disclosure - Subsequent Events- Thimble (Details)", "role": "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "shortName": "Subsequent Events- Thimble (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R12": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1011012 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "if15f88f6e42042c7a5b0d45dde439a8b_D20201201-20201231", "decimals": "0", "lang": "en-US", "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "id3e63e3841ed4a26b0ea98a0f6d4b255_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1013013 - Statement - Condensed Consolidated Statement of Changes in Stockholders' (Deficit) Equity", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib232584757f946fba6ded76b7103d7f6_I20201130", "decimals": "INF", "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i8d1fa1cb19124d7a9d933da3bb7e5355_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1015014 - Statement - Condensed Consolidated Statement of Cash Flows", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "shortName": "Condensed Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iffcca3b6623c4ab7b7725824ad60163d_D20210101-20210930", "decimals": "0", "lang": "en-US", "name": "pear:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1412436 - Statement - Condensed Consolidated Statements of Operations- Thimble (Parenthetical)", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "shortName": "Condensed Consolidated Statements of Operations- Thimble (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1414437 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity- Thimble (Parenthetical)", "role": "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity- Thimble (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - NATURE OF BUSINESS", "role": "http://www.peartherapeutics.com/role/NATUREOFBUSINESS", "shortName": "NATURE OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110103 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS 10K", "role": "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "shortName": "CONSOLIDATED BALANCE SHEETS 10K", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116104 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i83f4d3d5b08941bfb8a0183f19f67e87_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119105 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "role": "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i83f4d3d5b08941bfb8a0183f19f67e87_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - INDEBTEDNESS", "role": "http://www.peartherapeutics.com/role/INDEBTEDNESS", "shortName": "INDEBTEDNESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128107 - Disclosure - LICENSE AGREEMENTS", "role": "http://www.peartherapeutics.com/role/LICENSEAGREEMENTS", "shortName": "LICENSE AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS", "role": "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTS", "shortName": "COLLABORATION AND LICENSE AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136109 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pear:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140110 - Disclosure - CONVERTIBLE PREFERRED STOCK", "role": "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCK", "shortName": "CONVERTIBLE PREFERRED STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pear:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143111 - Disclosure - COMMON STOCK", "role": "http://www.peartherapeutics.com/role/COMMONSTOCK", "shortName": "COMMON STOCK", "subGroupType": "", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146112 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152113 - Disclosure - INCOME TAXES", "role": "http://www.peartherapeutics.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS 10K (Parenthetical)", "role": "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10KParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS 10K (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157114 - Disclosure - NET LOSS PER SHARE", "role": "http://www.peartherapeutics.com/role/NETLOSSPERSHARE", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161115 - Disclosure - RELATED-PARTY TRANSACTIONS", "role": "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2163116 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2166117 - Disclosure - Description of Organization and Business Operations", "role": "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperations", "shortName": "Description of Organization and Business Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2168118 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "pear:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2174119 - Disclosure - Initial Public Offering", "role": "http://www.peartherapeutics.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "pear:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pear:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176120 - Disclosure - Private Placement", "role": "http://www.peartherapeutics.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pear:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2178121 - Disclosure - Related Party Transactions", "role": "http://www.peartherapeutics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2182122 - Disclosure - Commitments", "role": "http://www.peartherapeutics.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2184123 - Disclosure - Stockholder's Equity", "role": "http://www.peartherapeutics.com/role/StockholdersEquity", "shortName": "Stockholder's Equity", "subGroupType": "", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS 10Q", "role": "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "shortName": "CONSOLIDATED BALANCE SHEETS 10Q", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pear:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2186124 - Disclosure - Warrants", "role": "http://www.peartherapeutics.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pear:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2188125 - Disclosure - Fair Value Measurements", "role": "http://www.peartherapeutics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2194126 - Disclosure - Subsequent Events", "role": "http://www.peartherapeutics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2269202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "icca2360aeca44f89b83c78324980f729_D20201201-20201231", "decimals": null, "lang": "en-US", "name": "pear:EmerginggrowthcompanyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - INDEBTEDNESS (Tables)", "role": "http://www.peartherapeutics.com/role/INDEBTEDNESSTables", "shortName": "INDEBTEDNESS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS 10Q (Parenthetical)", "role": "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10QParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS 10Q (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Tables)", "role": "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSTables", "shortName": "COLLABORATION AND LICENSE AGREEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341308 - Disclosure - CONVERTIBLE PREFERRED STOCK (Tables)", "role": "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKTables", "shortName": "CONVERTIBLE PREFERRED STOCK (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344309 - Disclosure - COMMON STOCK (Tables)", "role": "http://www.peartherapeutics.com/role/COMMONSTOCKTables", "shortName": "COMMON STOCK (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347310 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353311 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.peartherapeutics.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2358312 - Disclosure - NET LOSS PER SHARE (Tables)", "role": "http://www.peartherapeutics.com/role/NETLOSSPERSHARETables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2370314 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2379315 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2389316 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.peartherapeutics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i8d1fa1cb19124d7a9d933da3bb7e5355_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - NATURE OF BUSINESS - Narrative (Details)", "role": "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails", "shortName": "NATURE OF BUSINESS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - NATURE OF BUSINESS - Organization (Details)", "role": "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "shortName": "NATURE OF BUSINESS - Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie10726df09ba4539982c3ad68f4ab77e_D20211203-20211203", "decimals": "-5", "lang": "en-US", "name": "pear:ProceedsFromReverseRecapitalizationTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "pear:DeferredOfferingCostsCurrentAndNonCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "role": "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "pear:DeferredOfferingCostsCurrentAndNonCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i1c5c941006324c408565ff8d928b4eff_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "role": "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i1c5c941006324c408565ff8d928b4eff_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iafc526304ae246c7aa6fc1ca2834b8ba_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Fair Value (Details)", "role": "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iafc526304ae246c7aa6fc1ca2834b8ba_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "role": "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ia01e938a022a4156bd7deb51719ff8ee_D20190101-20190930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i344badbd050443e48d1eb7c8416bfa86_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)", "role": "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i344badbd050443e48d1eb7c8416bfa86_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i76c1f4571fdf4bc0bfa54037a9aa3ee1_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Roll Forward (Details)", "role": "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "shortName": "FAIR VALUE MEASUREMENTS - Level 3 Roll Forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i1c0a0365d3ae48ab85686ebb98fdceb1_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i37f4a3675923452a99cce01cbe39ecdf_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT", "role": "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i37f4a3675923452a99cce01cbe39ecdf_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie48e5dd8daf1410a9d35e1c3dca90ec8_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - INDEBTEDNESS - Perceptive Credit Facility (Details)", "role": "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "shortName": "INDEBTEDNESS - Perceptive Credit Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i0a35a49d078f4beab200ee9a5e5db57d_I20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - INDEBTEDNESS - Schedule of Debt (Details)", "role": "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails", "shortName": "INDEBTEDNESS - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iacdaddf334d44b88be4d605a735accb7_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - INDEBTEDNESS - Future Minimum Payments Due (Details)", "role": "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails", "shortName": "INDEBTEDNESS - Future Minimum Payments Due (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - INDEBTEDNESS - SVB Term Loan (Details)", "role": "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "shortName": "INDEBTEDNESS - SVB Term Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i88e14a74f32840dcbc70db2755cf9aef_I20210709", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - LICENSE AGREEMENTS (Details)", "role": "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails", "shortName": "LICENSE AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i20fc8c69a92d4cd0bacaba4969414c50_D20190101-20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Sandoz (Details)", "role": "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "shortName": "COLLABORATION AND LICENSE AGREEMENTS - Sandoz (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i35376395a7d940db903879f394379f3b_I20180430", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Sandoz Note Payable (Details)", "role": "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "shortName": "COLLABORATION AND LICENSE AGREEMENTS - Sandoz Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iab05bde0a7ca4d0fb93ac9dcf8bd246d_I20190917", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Novartis (Details)", "role": "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "shortName": "COLLABORATION AND LICENSE AGREEMENTS - Novartis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i1968cf7d39d84da4a053883aba4b0338_D20190101-20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iafc526304ae246c7aa6fc1ca2834b8ba_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435420 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Change in Deferred Revenue (Details)", "role": "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "shortName": "COLLABORATION AND LICENSE AGREEMENTS - Change in Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "iafc526304ae246c7aa6fc1ca2834b8ba_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i941b9d01abd54be1bb0ee1954c3d1319_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT (Parenthetical)", "role": "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i941b9d01abd54be1bb0ee1954c3d1319_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "role": "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - COMMITMENTS AND CONTINGENCIES - Operating Leases (Details)", "role": "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details)", "role": "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "shortName": "CONVERTIBLE PREFERRED STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - COMMON STOCK (Details)", "role": "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "shortName": "COMMON STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449426 - Disclosure - STOCK-BASED COMPENSATION - Common Stock Options (Details)", "role": "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails", "shortName": "STOCK-BASED COMPENSATION - Common Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i52ba663c509a4eb8811b523a4464b32e_D20210101-20210930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450427 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)", "role": "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails", "shortName": "STOCK-BASED COMPENSATION - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i52ba663c509a4eb8811b523a4464b32e_D20210101-20210930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451428 - Disclosure - STOCK-BASED COMPENSATION - Stock Based Compensation Expense (Details)", "role": "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails", "shortName": "STOCK-BASED COMPENSATION - Stock Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ica1bbe3f01614888b839112a080bd58b_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454429 - Disclosure - INCOME TAXES - Reconciliation of Tax Rate (Details)", "role": "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails", "shortName": "INCOME TAXES - Reconciliation of Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455430 - Disclosure - INCOME TAXES - Deferred Tax Assets (Details)", "role": "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails", "shortName": "INCOME TAXES - Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ib003ecd93b97411ebbef2f4bd6fbea40_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008009 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456431 - Disclosure - INCOME TAXES - Additional Information (Details)", "role": "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails", "shortName": "INCOME TAXES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459432 - Disclosure - NET LOSS PER SHARE - Antidilituve Securities (Details)", "role": "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails", "shortName": "NET LOSS PER SHARE - Antidilituve Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i305b9a8b1a51426da94cc2961cae4d6e_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i8d1fa1cb19124d7a9d933da3bb7e5355_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460433 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Per Share (Details)", "role": "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails", "shortName": "NET LOSS PER SHARE - Basic and Diluted Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i65c5bb89daa3497d814bf3a1f0333112_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462434 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "role": "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i52a68a0c0e854efbb905a1ee45b706f1_D20201201-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i43bbb046005b487e92a930b1a9c8e2f6_I20171228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465435 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "idde4701e8e8b4cf2b92e421f8fb1c270_I20210621", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "if77f42c9d4af45e8900d9952b831f534_I20210204", "decimals": "2", "first": true, "lang": "en-US", "name": "pear:PercentageOfNetAssetHeldInTheTrustAccount", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467438 - Disclosure - Description of Organization and Business Operations - Additional Information (Details)", "role": "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "shortName": "Description of Organization and Business Operations - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "if77f42c9d4af45e8900d9952b831f534_I20210204", "decimals": "2", "first": true, "lang": "en-US", "name": "pear:PercentageOfNetAssetHeldInTheTrustAccount", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471439 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "ie3ae1f5edf5946b99b6f0e1f2090035a_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472440 - Disclosure - Summary of Significant Accounting Policies - Summary of Class A Common Stock Subject to Possible Redemption (Details)", "role": "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Class A Common Stock Subject to Possible Redemption (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i3fd78385ee6f43359cfa59e4ba05914e_D20210101-20210930", "decimals": "0", "lang": "en-US", "name": "pear:ProceedsAllocatedToPublicWarrants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i8d1fa1cb19124d7a9d933da3bb7e5355_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473441 - Disclosure - Summary of Significant Accounting Policies - Summary Of Basic And Diluted Net Income (Loss) Per Common Share (Details)", "role": "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "shortName": "Summary of Significant Accounting Policies - Summary Of Basic And Diluted Net Income (Loss) Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R99": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i45b3621674bc4f6cb6ebc9a879725e09_D20210204-20210204", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommonStockConversionBasis", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475442 - Disclosure - Initial Public Offering - Additional Information (Detail)", "role": "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "shortName": "Initial Public Offering - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "pear-20211223.htm", "contextRef": "i60d35593f3c34ef7bfb51f6ddbfacaa4_I20210204", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } } }, "segmentCount": 151, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r739" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_A2013StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A2013 Stock Incentive Plan", "label": "A2013 Stock Incentive Plan [Member]", "terseLabel": "2013 Stock Incentive Plan" } } }, "localname": "A2013StockIncentivePlanMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_AccruedCompensationAndRelatedBenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Compensation And Related Benefits", "label": "Accrued Compensation And Related Benefits [Member]", "terseLabel": "Accrued Compensation and Related Benefits" } } }, "localname": "AccruedCompensationAndRelatedBenefitsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_AccruedOfferingCosts": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued offering costs.", "label": "Accrued Offering Costs", "terseLabel": "Accrued offering costs" } } }, "localname": "AccruedOfferingCosts", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "pear_AdministrativeServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administrative Services Agreement", "label": "Administrative Services Agreement [Member]", "terseLabel": "Administrative Services Agreement" } } }, "localname": "AdministrativeServicesAgreementMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_AmendedForwardContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Forward Contracts", "label": "Amended Forward Contracts [Member]", "verboseLabel": "Amended Forward Contracts [Member]" } } }, "localname": "AmendedForwardContractsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_AnchorInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anchor investor member.", "label": "Anchor Investor [Member]", "terseLabel": "Anchor Investor [Member]" } } }, "localname": "AnchorInvestorMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "domainItemType" }, "pear_BeHealthSolutionsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BeHealth Solutions,\u00a0LLC", "label": "BeHealth Solutions,\u00a0LLC [Member]", "terseLabel": "BeHealth Solutions,\u00a0LLC" } } }, "localname": "BeHealthSolutionsLLCMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "domainItemType" }, "pear_BostonMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boston, Massachusetts", "label": "Boston, Massachusetts [Member]", "terseLabel": "Boston, Massachusetts" } } }, "localname": "BostonMassachusettsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_BusinessCombinationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination Agreement", "label": "Business Combination Agreement [Member]", "terseLabel": "Business Combination Agreement" } } }, "localname": "BusinessCombinationAgreementMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "pear_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19", "label": "COVID-19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_CapitalizedMilestonePaymentLiabilityUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalized Milestone Payment Liability, Useful Life", "label": "Capitalized Milestone Payment Liability, Useful Life", "terseLabel": "Useful life of capitalized milestone payments" } } }, "localname": "CapitalizedMilestonePaymentLiabilityUsefulLife", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "durationItemType" }, "pear_CertainEligibleEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain Eligible Employees", "label": "Certain Eligible Employees [Member]", "terseLabel": "Certain Eligible Employees" } } }, "localname": "CertainEligibleEmployeesMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "pear_ChangeInContractWithCustomerLiabilityRollforwardRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Contract with Customer, Liability, Rollforward", "label": "Change in Contract with Customer, Liability, Rollforward [Roll Forward]", "terseLabel": "Change in Contract with Customer, Liability, Rollforward [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollforwardRollForward", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "pear_ChangeInFairValueOfPromissoryNote": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of promissory note.", "label": "Change In Fair Value of Promissory Note", "negatedLabel": "Change in fair value of promissory note", "verboseLabel": "Change in fair value of promissory note" } } }, "localname": "ChangeInFairValueOfPromissoryNote", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "pear_ChiefExecutiveOfficerAndCertainEligibleEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer And Certain Eligible Employees", "label": "Chief Executive Officer And Certain Eligible Employees [Member]", "terseLabel": "Chief Executive Officer And Certain Eligible Employees" } } }, "localname": "ChiefExecutiveOfficerAndCertainEligibleEmployeesMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "pear_ClassACommonStockAndRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class a common stock and redeemable warrant member.", "label": "Class A Common Stock And Redeemable Warrant [Member]", "terseLabel": "Class A Common Stock And Redeemable Warrant [Member]" } } }, "localname": "ClassACommonStockAndRedeemableWarrantMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_ClassOfWarrantOrRightExercisableForCashOrOnACashlessBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercisable for cash or on a cashless basis.", "label": "Class Of Warrant Or Right Exercisable For Cash Or On A Cashless Basis", "terseLabel": "Warrant exercisable for cash or on a cashless basis" } } }, "localname": "ClassOfWarrantOrRightExercisableForCashOrOnACashlessBasis", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "pear_ClassOfWarrantOrRightsIssuePricePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Rights Issue Price Per Warrant.", "label": "Class Of Warrant Or Rights Issue Price Per Warrant", "terseLabel": "Class of warrant or rights issue price per warrant" } } }, "localname": "ClassOfWarrantOrRightsIssuePricePerWarrant", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "pear_ClassOfWarrantsAndRightsIssuedDuringThePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants and rights Issued during the period .", "label": "Class Of Warrants and Rights Issued During the Period", "terseLabel": "Class of warrant or right, issued during the period" } } }, "localname": "ClassOfWarrantsAndRightsIssuedDuringThePeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "pear_ClassOfWarrantsAndRightsIssuedPricePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants and rights issued, price per warrant .", "label": "Class Of Warrants and Rights Issued Price Per Warrant", "terseLabel": "Class of warrant or right, issue price" } } }, "localname": "ClassOfWarrantsAndRightsIssuedPricePerWarrant", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "pear_ClassOfWarrantsExercisePriceAdjustmentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants, exercise price adjustment percentage.", "label": "Class of warrants exercise price adjustment percentage", "terseLabel": "Class of warrants, exercise price adjustment percentage" } } }, "localname": "ClassOfWarrantsExercisePriceAdjustmentPercentage", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "pear_ClassOfWarrantsOrRightsNumberOfWarrantsIssuedDuringThePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrants Or Rights Number Of Warrants Issued During The Period.", "label": "Class Of Warrants Or Rights Number Of Warrants Issued During The Period", "terseLabel": "Private placement warrants issued" } } }, "localname": "ClassOfWarrantsOrRightsNumberOfWarrantsIssuedDuringThePeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "pear_ClassOfWarrantsRedemptionNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants, redemption notice period.", "label": "Class of warrants redemption notice period", "terseLabel": "Class of warrants, redemption notice period" } } }, "localname": "ClassOfWarrantsRedemptionNoticePeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_ClassOfWarrantsRedemptionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants, redemption price per unit.", "label": "Class of warrants redemption price per unit", "terseLabel": "Class of warrants, redemption price per unit" } } }, "localname": "ClassOfWarrantsRedemptionPricePerUnit", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "pear_CollaborationAndLicenseRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration And License Revenue", "label": "Collaboration And License Revenue [Member]", "terseLabel": "Collaboration and license revenue" } } }, "localname": "CollaborationAndLicenseRevenueMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "domainItemType" }, "pear_CollaborativeArrangementDeferredPaymentsToCounterParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Deferred Payments To Counter Party", "label": "Collaborative Arrangement, Deferred Payments To Counter Party", "terseLabel": "Deferred payments" } } }, "localname": "CollaborativeArrangementDeferredPaymentsToCounterParty", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "monetaryItemType" }, "pear_CommonStockAchievingRupeesFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock achieving Rupees Fifteen.", "label": "Common stock achieving Rupees Fifteen [Member]", "terseLabel": "Common stock achieving Rupees Fifteen [Member]" } } }, "localname": "CommonStockAchievingRupeesFifteenMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_CommonStockAchievingRupeesSeventeenPointFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock achieving Rupees Seventeen Point Five.", "label": "Common stock achieving Rupees Seventeen Point Five [Member]", "terseLabel": "Common stock achieving Rupees Seventeen Point Five [Member]" } } }, "localname": "CommonStockAchievingRupeesSeventeenPointFiveMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_CommonStockAchievingRupeesTwelvePointFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock achieving Rupees Twelve Point Five.", "label": "Common stock achieving Rupees Twelve Point Five [Member]", "terseLabel": "Common stock achieving Rupees Twelve Point Five [Member]" } } }, "localname": "CommonStockAchievingRupeesTwelvePointFiveMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_CommonStockInConnectionWithMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, In Connection With Merger", "label": "Common Stock, In Connection With Merger [Member]", "terseLabel": "Common Stock, In Connection With Merger" } } }, "localname": "CommonStockInConnectionWithMergerMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "domainItemType" }, "pear_CommonStockSharesReservedForIssuanceOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Shares Reserved For Issuance Of Warrants", "label": "Common Stock, Shares Reserved For Issuance Of Warrants", "terseLabel": "Shares reserved for the issuance of warrants (in shares)" } } }, "localname": "CommonStockSharesReservedForIssuanceOfWarrants", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails" ], "xbrltype": "sharesItemType" }, "pear_CommonStockSubjectToMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Subject To Merger", "label": "Common Stock, Subject To Merger [Member]", "terseLabel": "Common Stock, Subject To Merger" } } }, "localname": "CommonStockSubjectToMergerMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "domainItemType" }, "pear_CommonStockVotingRightsVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Votes", "label": "Common Stock, Voting Rights, Votes", "terseLabel": "Number of votes" } } }, "localname": "CommonStockVotingRightsVotes", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails" ], "xbrltype": "integerItemType" }, "pear_ContributionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contribution One", "label": "Contribution One [Member]", "terseLabel": "Contribution One" } } }, "localname": "ContributionOneMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_ContributionTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contribution Two", "label": "Contribution Two [Member]", "terseLabel": "Contribution Two" } } }, "localname": "ContributionTwoMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_ConvertiblePreferredStockPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Policy", "label": "Convertible Preferred Stock, Policy [Policy Text Block]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockPolicyPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "pear_DataFoundryCloudSubscriptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Data Foundry Cloud Subscription", "label": "Data Foundry Cloud Subscription [Member]", "terseLabel": "Data Foundry Cloud Subscription" } } }, "localname": "DataFoundryCloudSubscriptionMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "pear_DebtCovenant1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant 1", "label": "Debt Covenant 1 [Member]", "terseLabel": "Debt Covenant 1" } } }, "localname": "DebtCovenant1Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_DebtCovenant2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant 2", "label": "Debt Covenant 2 [Member]", "terseLabel": "Debt Covenant 2" } } }, "localname": "DebtCovenant2Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_DebtCovenant3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant 3", "label": "Debt Covenant 3 [Member]", "terseLabel": "Debt Covenant 3" } } }, "localname": "DebtCovenant3Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_DebtInstrumentCovenantComplianceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance", "label": "Debt Instrument, Covenant Compliance [Axis]", "terseLabel": "Debt Instrument, Covenant Compliance [Axis]" } } }, "localname": "DebtInstrumentCovenantComplianceAxis", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "pear_DebtInstrumentCovenantComplianceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance [Domain]", "label": "Debt Instrument, Covenant Compliance [Domain]", "terseLabel": "Debt Instrument, Covenant Compliance [Domain]" } } }, "localname": "DebtInstrumentCovenantComplianceDomain", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_DebtInstrumentCovenantComplianceMinimumAggregateCashBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance, Minimum Aggregate Cash Balance", "label": "Debt Instrument, Covenant Compliance, Minimum Aggregate Cash Balance", "terseLabel": "Minimum aggregate cash balance" } } }, "localname": "DebtInstrumentCovenantComplianceMinimumAggregateCashBalance", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "pear_DebtInstrumentCovenantComplianceRevenuesForTheTrailing12MonthPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance, Revenues For The Trailing 12-Month Period", "label": "Debt Instrument, Covenant Compliance, Revenues For The Trailing 12-Month Period", "terseLabel": "Revenues for trailing 12-month period" } } }, "localname": "DebtInstrumentCovenantComplianceRevenuesForTheTrailing12MonthPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "pear_DebtInstrumentDebtDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Debt Discount Percentage", "label": "Debt Instrument, Debt Discount Percentage", "terseLabel": "Discount percentage" } } }, "localname": "DebtInstrumentDebtDiscountPercentage", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "percentItemType" }, "pear_DebtInstrumentDeferredGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Deferred Gain", "label": "Debt Instrument, Deferred Gain", "terseLabel": "Deferred gain" } } }, "localname": "DebtInstrumentDeferredGain", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "monetaryItemType" }, "pear_DebtInstrumentDiscountDeferredGainAmortizationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Discount, Deferred Gain Amortization Period", "label": "Debt Instrument, Discount, Deferred Gain Amortization Period", "terseLabel": "Deferred gain amortization period" } } }, "localname": "DebtInstrumentDiscountDeferredGainAmortizationPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "durationItemType" }, "pear_DebtInstrumentExtinguishmentOfDebtPercentageOfBorrowings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Extinguishment Of Debt, Percentage Of Borrowings", "label": "Debt Instrument, Extinguishment Of Debt, Percentage Of Borrowings", "terseLabel": "Percentage of borrowings extinguished" } } }, "localname": "DebtInstrumentExtinguishmentOfDebtPercentageOfBorrowings", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "percentItemType" }, "pear_DebtInstrumentFloorInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Floor rate" } } }, "localname": "DebtInstrumentFloorInterestRate", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "pear_DebtInstrumentPeriodicPaymentPercentageOfPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percentage Of Principal", "label": "Debt Instrument, Periodic Payment, Percentage Of Principal", "terseLabel": "Percentage of principal, payment" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentageOfPrincipal", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "pear_DebtInstrumentPeriodicPaymentPercentageOfVotingStockTriggeringRepayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percentage Of Voting Stock Triggering Repayment", "label": "Debt Instrument, Periodic Payment, Percentage Of Voting Stock Triggering Repayment", "terseLabel": "Percentage of voting stock triggering repayment" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentageOfVotingStockTriggeringRepayment", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "pear_DebtInstrumentPeriodicPaymentReturnOnPrepaymentAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment, Return On Prepayment Amount", "label": "Debt Instrument, Periodic Payment, Return On Prepayment Amount", "terseLabel": "Return on prepaid amount" } } }, "localname": "DebtInstrumentPeriodicPaymentReturnOnPrepaymentAmount", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "pureItemType" }, "pear_DebtInstrumentTerminationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Fee", "label": "Debt Instrument, Termination Fee", "terseLabel": "Termination fee" } } }, "localname": "DebtInstrumentTerminationFee", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "pear_DeferredOfferingCostsCurrentAndNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Offering Costs, Current And Non-Current", "label": "Deferred Offering Costs, Current And Non-Current", "terseLabel": "Capitalized deferred offering costs" } } }, "localname": "DeferredOfferingCostsCurrentAndNonCurrent", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "pear_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction", "label": "Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pear_DeferredOfferingCostsNoncurrent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Offering Costs Noncurrent.", "label": "Deferred Offering Costs, Noncurrent", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsNoncurrent", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "pear_DeferredUnderwritingCommissionPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commission per unit.", "label": "Deferred Underwriting Commission Per Unit", "terseLabel": "Deferred underwriting commission per unit" } } }, "localname": "DeferredUnderwritingCommissionPerUnit", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "pear_DeferredUnderwritingFeePayableNoncurrent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Underwriting Fee Payable Noncurrent.", "label": "Deferred Underwriting Fee Payable Noncurrent", "terseLabel": "Deferred underwriting fee payable" } } }, "localname": "DeferredUnderwritingFeePayableNoncurrent", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "pear_DefinedContributionPlanEmployerMatchingContributionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Matching Contribution", "label": "Defined Contribution Plan, Employer Matching Contribution [Axis]", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution [Axis]" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionAxis", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "pear_DefinedContributionPlanEmployerMatchingContributionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Matching Contribution [Domain]", "label": "Defined Contribution Plan, Employer Matching Contribution [Domain]", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution [Domain]" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionDomain", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_DissolutionExpenseInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Dissolution expense interest .", "label": "Dissolution Expense Interest", "terseLabel": "Dissolution expense interest" } } }, "localname": "DissolutionExpenseInterest", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "pear_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentPercent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Provision To Return Adjustment, Percent", "label": "Effective Income Tax Rate Reconciliation, Provision To Return Adjustment, Percent", "terseLabel": "Provision to return adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentPercent", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "pear_EmerginggrowthcompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company .", "label": "EmergingGrowthCompany [Policy Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmerginggrowthcompanyPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "pear_EventAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event.", "label": "Event [Axis]", "terseLabel": "Event [Axis]" } } }, "localname": "EventAxis", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_EventDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event.", "label": "Event [Domain]", "terseLabel": "Event [Domain]" } } }, "localname": "EventDomain", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_FounderSharesLockInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares lock in period.", "label": "Founder Shares Lock In Period", "terseLabel": "Founder shares lock in period" } } }, "localname": "FounderSharesLockInPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares member.", "label": "Founder Shares [Member]", "terseLabel": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "domainItemType" }, "pear_GainLossOnDeferredGainOnNotePayable": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Deferred Gain On Note Payable", "label": "Gain (Loss) On Deferred Gain On Note Payable", "negatedTerseLabel": "Amortization of deferred gain on note payable to collaboration partner", "terseLabel": "Amortization of deferred gain on note payable to collaboration partner" } } }, "localname": "GainLossOnDeferredGainOnNotePayable", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pear_GainLossOnIssuanceOfConvertiblePreferredStock": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Issuance Of Convertible Preferred Stock", "label": "Gain (Loss) On Issuance Of Convertible Preferred Stock", "negatedTerseLabel": "Loss on issuance of convertible preferred stock", "terseLabel": "Loss on issuance of convertible preferred stock" } } }, "localname": "GainLossOnIssuanceOfConvertiblePreferredStock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pear_GainLossOnRepurchaseOfConvertiblePreferredStock": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Repurchase Of Convertible Preferred Stock", "label": "Gain (Loss) On Repurchase Of Convertible Preferred Stock", "negatedTerseLabel": "Loss on repurchase of convertible preferred stock", "terseLabel": "Loss on repurchase of convertible preferred stock" } } }, "localname": "GainLossOnRepurchaseOfConvertiblePreferredStock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "monetaryItemType" }, "pear_IncludingOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Including Over-Allotment Option", "label": "Including Over-Allotment Option [Member]", "terseLabel": "Including Over-Allotment Option" } } }, "localname": "IncludingOverAllotmentOptionMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering.", "label": "Initial Public Offering [Abstract]" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.peartherapeutics.com/20211223", "xbrltype": "stringItemType" }, "pear_InitialPublicOfferingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering.", "label": "Initial Public Offering [Line Items]", "verboseLabel": "Initial Public Offering [Line Items]" } } }, "localname": "InitialPublicOfferingLineItems", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_InitialPublicOfferingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering.", "label": "Initial Public Offering [Table]", "verboseLabel": "Initial Public Offering [Table]" } } }, "localname": "InitialPublicOfferingTable", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering.", "label": "Initial Public Offering [Text Block]", "terseLabel": "Initial public offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "pear_InitialValueOfCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial value of common stock subject to possible redemption.", "label": "Initial Value Of Common Stock Subject To Possible Redemption", "terseLabel": "Initial classification of common stock subject to possible redemption" } } }, "localname": "InitialValueOfCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "pear_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on marketable securities held in trust account.", "label": "Interest Earned On Marketable Securities Held In Trust Account", "negatedLabel": "Interest earned on marketable securities held in Trust Account" } } }, "localname": "InterestEarnedOnMarketableSecuritiesHeldInTrustAccount", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "pear_InventionScienceFundILLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Invention Science Fund I, LLC", "label": "Invention Science Fund I, LLC [Member]", "terseLabel": "Invention Science Fund I, LLC" } } }, "localname": "InventionScienceFundILLCMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_LesseeOperatingLeaseExtensionOfLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Extension Of Lease Term", "label": "Lessee, Operating Lease, Extension Of Lease Term", "terseLabel": "Extended lease term" } } }, "localname": "LesseeOperatingLeaseExtensionOfLeaseTerm", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "durationItemType" }, "pear_LongTermDebtMaturityYearFiveAndThereafter": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Debt Maturity, Year Five And Thereafter", "label": "Long Term Debt Maturity, Year Five And Thereafter", "terseLabel": "Year Five and Thereafter" } } }, "localname": "LongTermDebtMaturityYearFiveAndThereafter", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "pear_LongTermDebtMaturityYearFourAndThereafter": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_2": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, Year Four And Thereafter", "label": "Long-Term Debt, Maturity, Year Four And Thereafter", "terseLabel": "Year Five" } } }, "localname": "LongTermDebtMaturityYearFourAndThereafter", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "pear_LongTermPurchaseCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment", "label": "Long Term Purchase Commitment", "terseLabel": "Purchase liability" } } }, "localname": "LongTermPurchaseCommitment", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "pear_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "xxxMarketable Securities Held in Trust Account .", "label": "Marketable Securities Held in Trust Account [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "MarketableSecuritiesHeldInTrustAccountPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "pear_MaturityDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity days .", "label": "Maturity days", "terseLabel": "Maturity days" } } }, "localname": "MaturityDays", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "pear_MeasurementInputExpectedVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Expected Volatility [Member]", "label": "Measurement Input Expected Volatility [Member]", "terseLabel": "Measurement Input Expected Volatility [Member]" } } }, "localname": "MeasurementInputExpectedVolatilityMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "pear_MeasurementInputMarketPriceOfPublicSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Market Price of Public Shares [Member]", "label": "Measurement Input Market Price of Public Shares [Member]", "terseLabel": "Measurement Input Market Price of Public Shares [Member]" } } }, "localname": "MeasurementInputMarketPriceOfPublicSharesMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "pear_MeasurementInputValuePerPrivateWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Value Per Private Warrant [Member]", "label": "Measurement Input Value Per Private Warrant [Member]", "terseLabel": "Measurement Input Value Per Private Warrant [Member]" } } }, "localname": "MeasurementInputValuePerPrivateWarrantMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "pear_MilestonePaymentLiability": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment, Liability", "label": "Milestone Payment, Liability", "terseLabel": "Milestone payment" } } }, "localname": "MilestonePaymentLiability", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "pear_MilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment", "label": "Milestone Payment [Member]", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePaymentMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "domainItemType" }, "pear_MilestonePaymentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payments, Policy", "label": "Milestone Payments, Policy [Policy Text Block]", "terseLabel": "Milestone Payments" } } }, "localname": "MilestonePaymentsPolicyPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "pear_MilestoneTrancheLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Tranche Liability", "label": "Milestone Tranche Liability", "terseLabel": "Milestone tranche liability" } } }, "localname": "MilestoneTrancheLiability", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "pear_MilestoneTranchePercentageOfShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Tranche, Percentage Of Shareholders", "label": "Milestone Tranche, Percentage Of Shareholders", "terseLabel": "Percentage of shareholders" } } }, "localname": "MilestoneTranchePercentageOfShareholders", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "percentItemType" }, "pear_MinimumLockInPeriodforSecRegistrationFromDateOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum lock In period\u00a0For SEC Registration From Date Of Business Combination.", "label": "Minimum lock In periodFor SEC Registration From Date Of Business Combination", "terseLabel": "Minimum lock In period\u00a0For SEC Registration From Date Of Business Combination" } } }, "localname": "MinimumLockInPeriodforSecRegistrationFromDateOfBusinessCombination", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_MinimumLockInPeriodforTransferAssignOrSellWarrantsAfterCompletionOfIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum lock In period\u00a0for transfer, assign or sell warrants after completion of IPO.", "label": "Minimum lock In periodfor transfer assign or sell warrants after completion of IPO", "terseLabel": "Minimum lock In period\u00a0for transfer, assign or sell warrants after completion of IPO" } } }, "localname": "MinimumLockInPeriodforTransferAssignOrSellWarrantsAfterCompletionOfIpo", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_MinimumLockInPeriodtoBecomeEffectiveAfterTheClosingOfTheInitialBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum lock In period\u00a0to become effective after the closing of the initial Business Combination.", "label": "Minimum lock In period to become effective after the closing of the initial Business Combination", "terseLabel": "Minimum lock In period\u00a0to become effective after the closing of the initial Business Combination" } } }, "localname": "MinimumLockInPeriodtoBecomeEffectiveAfterTheClosingOfTheInitialBusinessCombination", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_NetOperatingLossCarryforwardsResearchAndDevelopmentTaxCreditsAndAccruedExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Loss Carryforwards, Research And Development Tax Credits And Accrued Expenses", "label": "Net Operating Loss Carryforwards, Research And Development Tax Credits And Accrued Expenses [Member]", "terseLabel": "Net operating loss carryforwards, research and development tax credits and accrued expenses" } } }, "localname": "NetOperatingLossCarryforwardsResearchAndDevelopmentTaxCreditsAndAccruedExpensesMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "pear_NetTangibleAssetsForConsummationOfABusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net tangible assets For Consummation of a Business Combination .", "label": "Net tangible assets For Consummation of a Business Combination", "terseLabel": "Net tangible assets for consummation of a business combination" } } }, "localname": "NetTangibleAssetsForConsummationOfABusinessCombination", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "pear_NovartisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novartis", "label": "Novartis [Member]", "terseLabel": "Novartis" } } }, "localname": "NovartisMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "pear_NumberOfAdditionalWarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Additional Warrants Issued", "label": "Number Of Additional Warrants Issued", "terseLabel": "Additional warrants" } } }, "localname": "NumberOfAdditionalWarrantsIssued", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "integerItemType" }, "pear_NumberOfConsecutiveTradingDaysDeterminingLockInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days determining lock in period.", "label": "Number Of Consecutive Trading Days Determining Lock In Period", "terseLabel": "Number of consecutive trading days determining lock in period" } } }, "localname": "NumberOfConsecutiveTradingDaysDeterminingLockInPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_NumberOfConsecutiveTradingDaysForDeterminingSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days for determining share price.", "label": "Number of consecutive trading days for determining share price", "terseLabel": "Number of consecutive trading days for determining share price" } } }, "localname": "NumberOfConsecutiveTradingDaysForDeterminingSharePrice", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_NumberOfLicenseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of License Agreements", "label": "Number Of License Agreements", "terseLabel": "Number of license agreements" } } }, "localname": "NumberOfLicenseAgreements", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "pear_NumberOfSharesNotToTransfer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Shares not to transfer.", "label": "Number of Shares not to transfer", "terseLabel": "Number of Shares not to transfer" } } }, "localname": "NumberOfSharesNotToTransfer", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "pear_NumberOfSharesToBeReleased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares to be released", "label": "Number of shares to be released", "terseLabel": "Number of shares to be released" } } }, "localname": "NumberOfSharesToBeReleased", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "pear_NumberOfTradingDaysDeterminingLockInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days determining lock in period.", "label": "Number Of Trading Days Determining Lock In Period", "terseLabel": "Number of trading days determining lock in period" } } }, "localname": "NumberOfTradingDaysDeterminingLockInPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_NumberOfTradingDaysForDeterminingSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days for determining share price.", "label": "Number of trading days for determining share price", "terseLabel": "Number of trading days for determining share price" } } }, "localname": "NumberOfTradingDaysForDeterminingSharePrice", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_NumberOfWarrantsHeldInTrust": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Warrants held in trust.", "label": "Number of Warrants held in trust", "terseLabel": "Number of Warrants held in trust" } } }, "localname": "NumberOfWarrantsHeldInTrust", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "pear_NumberOfWarrantsToBeReleased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Warrants to be released.", "label": "Number of Warrants to be released", "terseLabel": "Number of Warrants to be released" } } }, "localname": "NumberOfWarrantsToBeReleased", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "pear_OfficeSpaceSecretarialAndAdministrativeServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office space, secretarial and administrative services.", "label": "Office space secretarial and administrative services [Member]", "terseLabel": "Office space secretarial and administrative services [Member]" } } }, "localname": "OfficeSpaceSecretarialAndAdministrativeServicesMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Future Minimum Payments, Due In Five Years And Thereafter", "label": "Operating Leases, Future Minimum Payments, Due In Five Years And Thereafter", "terseLabel": "2025 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "pear_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Not Subject to Expiration", "label": "Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "NOLs not subject to expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "pear_OrdinarysharessubjecttopossibleredemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OrdinarySharesSubjectToPossibleRedemption .", "label": "OrdinarySharesSubjectToPossibleRedemption [Policy Text Block]", "terseLabel": "Class\u00a0A Common Stock Subject to Possible Redemption" } } }, "localname": "OrdinarysharessubjecttopossibleredemptionPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "pear_OtherOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other offering costs .", "label": "Other Offering Costs", "terseLabel": "Other offering costs." } } }, "localname": "OtherOfferingCosts", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "pear_OtherShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Shareholders", "label": "Other Shareholders [Member]", "terseLabel": "Other Shareholders" } } }, "localname": "OtherShareholdersMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "pear_OzMergerSubIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oz merger sub, Inc.", "label": "Oz Merger Sub, Inc [Member]", "terseLabel": "Oz Merger Sub, Inc [Member]" } } }, "localname": "OzMergerSubIncMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "pear_PalantirTechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palantir Technologies, Inc", "label": "Palantir Technologies, Inc [Member]", "terseLabel": "Palantir Technologies, Inc" } } }, "localname": "PalantirTechnologiesIncMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "pear_PatentCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent Costs, Policy", "label": "Patent Costs, Policy [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "pear_PaymentOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Deferred Offering Costs", "label": "Payment Of Deferred Offering Costs", "negatedTerseLabel": "Payment of deferred offering costs" } } }, "localname": "PaymentOfDeferredOfferingCosts", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pear_PaymentsForDeferredUnderwritingExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for deferred underwriting expense .", "label": "Payments for deferred underwriting expense", "terseLabel": "Deferred underwriting fees" } } }, "localname": "PaymentsForDeferredUnderwritingExpense", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "pear_PaymentsForMilestonePayment": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Milestone Payment", "label": "Payments For Milestone Payment", "negatedTerseLabel": "Milestone based license fee payment", "terseLabel": "Milestone based license fee payment" } } }, "localname": "PaymentsForMilestonePayment", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pear_PercenatgeOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percenatge of shares .", "label": "Percenatge of shares", "terseLabel": "Percenatge of shares" } } }, "localname": "PercenatgeOfShares", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "pear_PercentageOfCapitalRaisedForBusinessCombinationToTotalEquityProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of capital raised for business combination to total equity proceeds.", "label": "Percentage Of Capital Raised For Business Combination To Total Equity Proceeds", "terseLabel": "Percentage of capital raised for business combination to total equity proceeds" } } }, "localname": "PercentageOfCapitalRaisedForBusinessCombinationToTotalEquityProceeds", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "pear_PercentageOfCompanysIssuedAndOutstandingSharesAfterTheInitialPublicOfferingOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of company's issued and outstanding shares after the initial public offering owned.", "label": "Percentage Of Companys Issued And Outstanding Shares After The Initial Public Offering Owned", "terseLabel": "Percentage of company's issued and outstanding shares after the Initial Public Offering Owned" } } }, "localname": "PercentageOfCompanysIssuedAndOutstandingSharesAfterTheInitialPublicOfferingOwned", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "pear_PercentageOfNetAssetHeldInTheTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net asset held in the trust account .", "label": "Percentage of Net asset Held in the trust account", "terseLabel": "Percentage of Net asset Held in the trust account" } } }, "localname": "PercentageOfNetAssetHeldInTheTrustAccount", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "pear_PercentageOfNumberOfSharesOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Number Of Shares Of Common Stock Outstanding.", "label": "Percentage Of Number Of Shares Of Common Stock Outstanding", "terseLabel": "Percentage of number of shares of common stock outstanding" } } }, "localname": "PercentageOfNumberOfSharesOfCommonStockOutstanding", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "pear_PerceptiveCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perceptive Credit Facility", "label": "Perceptive Credit Facility [Member]", "terseLabel": "Perceptive Credit Facility" } } }, "localname": "PerceptiveCreditFacilityMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "pear_PerceptiveCreditFacilityTranche1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perceptive Credit Facility, Tranche 1", "label": "Perceptive Credit Facility, Tranche 1 [Member]", "terseLabel": "Debt, Tranche 1" } } }, "localname": "PerceptiveCreditFacilityTranche1Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_PerceptiveCreditFacilityTranche2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perceptive Credit Facility, Tranche 2", "label": "Perceptive Credit Facility, Tranche 2 [Member]", "terseLabel": "Debt, Tranche 2" } } }, "localname": "PerceptiveCreditFacilityTranche2Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_PerceptiveCreditFacilityTranche3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perceptive Credit Facility, Tranche 3", "label": "Perceptive Credit Facility, Tranche 3 [Member]", "terseLabel": "Debt, Tranche 3" } } }, "localname": "PerceptiveCreditFacilityTranche3Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_PotentialMilestonePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Potential Milestone Payments", "label": "Potential Milestone Payments [Member]", "terseLabel": "Potential Milestone Payments" } } }, "localname": "PotentialMilestonePaymentsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "pear_PreferredStockConversionTriggeringNetProceedsMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Conversion Triggering, Net Proceeds Minimum", "label": "Preferred Stock, Conversion Triggering, Net Proceeds Minimum", "terseLabel": "Triggering event, minimum net proceeds" } } }, "localname": "PreferredStockConversionTriggeringNetProceedsMinimum", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "pear_PreferredStockConversionTriggeringPricePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Conversion Triggering Price, Price Per Share", "label": "Preferred Stock, Conversion Triggering Price, Price Per Share", "terseLabel": "Triggering price (in dollars per share)" } } }, "localname": "PreferredStockConversionTriggeringPricePricePerShare", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "pear_PrepaidExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expense", "label": "Prepaid Expense [Member]", "terseLabel": "Prepaid Expense" } } }, "localname": "PrepaidExpenseMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_PrivatePlacementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement.", "label": "Private Placement [Text Block]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "pear_PrivatePlacementWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement warrant", "label": "Private Placement warrant [Member]", "terseLabel": "Private Placement warrant [Member]" } } }, "localname": "PrivatePlacementWarrantMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement warrants .", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_ProceedsAllocatedToPublicWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds Allocated to Public Warrants.", "label": "Proceeds Allocated to Public Warrants", "negatedTerseLabel": "Proceeds allocated to Public Warrants" } } }, "localname": "ProceedsAllocatedToPublicWarrants", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "pear_ProceedsFromIssuanceInitialPublicOfferingPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance initial public offering per unit.", "label": "Proceeds From Issuance Initial Public Offering Per Unit", "verboseLabel": "Proceeds from issuance initial public offering per unit" } } }, "localname": "ProceedsFromIssuanceInitialPublicOfferingPerUnit", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "pear_ProceedsFromReverseRecapitalizationTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Reverse Recapitalization Transaction", "label": "Proceeds From Reverse Recapitalization Transaction", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromReverseRecapitalizationTransaction", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "pear_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note.", "label": "Promissory Note [Member]", "terseLabel": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_PublicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public[Member]", "label": "Public [Member]", "terseLabel": "Public [Member]" } } }, "localname": "PublicMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "pear_PublicShareRedeemablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public share redeemable percentage .", "label": "Public share Redeemable percentage", "terseLabel": "Public share redeemable percentage" } } }, "localname": "PublicShareRedeemablePercentage", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "pear_PublicWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrant.", "label": "Public Warrant [Member]", "terseLabel": "Public Warrant [Member]" } } }, "localname": "PublicWarrantMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrants [Member]", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_RaleighNorthCarolinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Raleigh, North Carolina", "label": "Raleigh, North Carolina [Member]", "terseLabel": "Raleigh, North Carolina" } } }, "localname": "RaleighNorthCarolinaMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_RecapitalizationExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recapitalization Exchange Ratio", "label": "Recapitalization Exchange Ratio", "terseLabel": "Exchange ratio" } } }, "localname": "RecapitalizationExchangeRatio", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "pureItemType" }, "pear_Red5GroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Red 5 Group, LLC", "label": "Red 5 Group, LLC [Member]", "terseLabel": "Red 5 Group, LLC" } } }, "localname": "Red5GroupLLCMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "domainItemType" }, "pear_ReimbursementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursement", "label": "Reimbursement [Member]", "terseLabel": "Reimbursement" } } }, "localname": "ReimbursementMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "domainItemType" }, "pear_ResearchAndDevelopmentLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research And Development Liabilities, Current", "label": "Research And Development Liabilities, Current", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentLiabilitiesCurrent", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "pear_ReverseRecapitalizationAccruedTransactionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reverse Recapitalization, Accrued Transaction Costs", "label": "Reverse Recapitalization, Accrued Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "ReverseRecapitalizationAccruedTransactionCosts", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "pear_SVBTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SVB Term Loan", "label": "SVB Term Loan [Member]", "terseLabel": "SVB Term Loan" } } }, "localname": "SVBTermLoanMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "domainItemType" }, "pear_SaleOfStockLiquidationRightWaivePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Liquidation Right Waive Period", "label": "Sale of Stock, Liquidation Right Waive Period", "terseLabel": "Liquidation right waive period" } } }, "localname": "SaleOfStockLiquidationRightWaivePeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "pear_SaleOfStockUnderwritingDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Underwriting Discount", "label": "Sale of Stock, Underwriting Discount", "terseLabel": "Sale of Stock, Underwriting Discount" } } }, "localname": "SaleOfStockUnderwritingDiscount", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "pear_SaleOfStockUnderwritingDiscountPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Underwriting Discount Per Unit", "label": "Sale of Stock, Underwriting Discount Per Unit", "terseLabel": "Sale of Stock, Underwriting Discount Per Share" } } }, "localname": "SaleOfStockUnderwritingDiscountPerUnit", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "pear_SaleOfStockUnderwritingOptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Underwriting Option Period", "label": "Sale of Stock, Underwriting Option Period", "terseLabel": "Sale of Stock, Underwriting Option Period" } } }, "localname": "SaleOfStockUnderwritingOptionPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_SanFranciscoCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "San Francisco, California", "label": "San Francisco, California [Member]", "terseLabel": "San Francisco, California" } } }, "localname": "SanFranciscoCaliforniaMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_SandozMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sandoz", "label": "Sandoz [Member]", "terseLabel": "Sandoz" } } }, "localname": "SandozMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesAAndBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A and B Preferred Stock", "label": "Series A and B Preferred Stock [Member]", "terseLabel": "Series A and B Preferred Stock" } } }, "localname": "SeriesAAndBPreferredStockMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Warrants", "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants" } } }, "localname": "SeriesAWarrantsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesCPreferredStockWarrant1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Preferred Stock, Warrant 1", "label": "Series C Preferred Stock, Warrant 1 [Member]", "terseLabel": "Series C Preferred Stock, Warrant 1" } } }, "localname": "SeriesCPreferredStockWarrant1Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesCPreferredStockWarrant2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Preferred Stock, Warrant 2", "label": "Series C Preferred Stock, Warrant 2 [Member]", "terseLabel": "Series C Preferred Stock, Warrant 2" } } }, "localname": "SeriesCPreferredStockWarrant2Member", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesD1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D-1 Preferred Stock", "label": "Series D-1 Preferred Stock [Member]", "terseLabel": "Series D-1 Preferred Stock" } } }, "localname": "SeriesD1PreferredStockMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesD2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D-2 Preferred Stock", "label": "Series D-2 Preferred Stock [Member]", "terseLabel": "Series D-2 Preferred Stock" } } }, "localname": "SeriesD2PreferredStockMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "pear_SeriesDWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Warrants", "label": "Series D Warrants [Member]", "terseLabel": "Series D Warrants" } } }, "localname": "SeriesDWarrantsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "pear_SettlementPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Payment", "label": "Settlement Payment [Member]", "terseLabel": "Settlement Payment" } } }, "localname": "SettlementPaymentMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "domainItemType" }, "pear_ShareBasedPaymentArrangementExpenseRelatedToRepurchaseOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Expense Related To Repurchase Of Common Stock", "label": "Share-Based Payment Arrangement, Expense Related To Repurchase Of Common Stock", "terseLabel": "Stock based compensation expenses related to repurchase of common stock" } } }, "localname": "ShareBasedPaymentArrangementExpenseRelatedToRepurchaseOfCommonStock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "pear_ShareBasedPaymentArrangementIncentiveOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Incentive Option", "label": "Share-Based Payment Arrangement, Incentive Option [Member]", "terseLabel": "Incentive options" } } }, "localname": "ShareBasedPaymentArrangementIncentiveOptionMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "pear_SharePriceEqualsOrExceedsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share price equals or exceeds member.", "label": "Share Price Equals Or Exceeds [Member]", "terseLabel": "Share Price Equals Or Exceeds [Member]" } } }, "localname": "SharePriceEqualsOrExceedsMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_SharePriceLessThanOrEqualsToUsdEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price Less Than Or Equals To USD Eighteen.", "label": "Share Price Less Than Or Equals To USD Eighteen [Member]", "terseLabel": "Share price less than or equals to 18 USD [Member]" } } }, "localname": "SharePriceLessThanOrEqualsToUsdEighteenMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_SharePriceLessThanOrEqualsToUsdNinePointTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price Less Than Or Equals To USD Nine Point Two.", "label": "Share Price Less Than Or Equals To USD Nine Point Two [Member]", "terseLabel": "Share Price Less Than Or Equals To USD Nine Point Two", "verboseLabel": "Share price less than or equals to 9.20 USD [Member]" } } }, "localname": "SharePriceLessThanOrEqualsToUsdNinePointTwoMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_SharePriceMoreThanOrEqualsToUsdEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price More Than Or Equals To USD Eighteen.", "label": "Share Price More Than Or Equals To USD Eighteen [Member]", "terseLabel": "Share price more than or equals to 18 USD [Member]" } } }, "localname": "SharePriceMoreThanOrEqualsToUsdEighteenMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_SharePriceRangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price Range [Axis]", "label": "Share Price Range [Axis]", "terseLabel": "Share Price Range [Axis]" } } }, "localname": "SharePriceRangeAxis", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_SharePriceRangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price Range [Domain]", "label": "Share Price Range [Domain]", "terseLabel": "Share Price Range [Domain]" } } }, "localname": "SharePriceRangeDomain", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_SharePurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Purchase", "label": "Share Purchase [Member]", "terseLabel": "Share Purchase" } } }, "localname": "SharePurchaseMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "pear_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sponsor member.", "label": "Sponsor [Member]", "terseLabel": "Sponsor [member]" } } }, "localname": "SponsorMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "pear_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants", "label": "Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "sharesItemType" }, "pear_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance costs.", "label": "Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "pear_StockRepurchasedDuringPeriodPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchased During Period, Price Per Share", "label": "Stock Repurchased During Period, Price Per Share", "terseLabel": "Shares repurchased (in dollars per share)" } } }, "localname": "StockRepurchasedDuringPeriodPricePerShare", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "perShareItemType" }, "pear_TargetEntityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Target entity.", "label": "Target Entity [Member]", "terseLabel": "Target Entity [Member]" } } }, "localname": "TargetEntityMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "pear_TemporaryEquityDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Decrease [Abstract].", "label": "Temporary Equity Decrease [Abstract]", "terseLabel": "Less" } } }, "localname": "TemporaryEquityDecreaseAbstract", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "stringItemType" }, "pear_TemporaryEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Disclosure", "label": "Temporary Equity Disclosure [Text Block]", "terseLabel": "CONVERTIBLE PREFERRED STOCK" } } }, "localname": "TemporaryEquityDisclosureTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCK" ], "xbrltype": "textBlockItemType" }, "pear_TemporaryEquityIncreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Increase [Abstract].", "label": "Temporary Equity Increase [Abstract]", "terseLabel": "Plus:" } } }, "localname": "TemporaryEquityIncreaseAbstract", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "stringItemType" }, "pear_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of Series D convertible preferred stock, net of issuance costs of $83 (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "pear_TenderOfferAggregateCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tender Offer, Aggregate Cost", "label": "Tender Offer, Aggregate Cost", "terseLabel": "Aggregate cost of tender offer" } } }, "localname": "TenderOfferAggregateCost", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "pear_TenderOfferFeesAndExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tender Offer, Fees And Expenses", "label": "Tender Offer, Fees And Expenses", "terseLabel": "Tender offer fees and expenses" } } }, "localname": "TenderOfferFeesAndExpenses", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "pear_TenderOfferPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tender Offer, Price Per Share", "label": "Tender Offer, Price Per Share", "terseLabel": "Tender offer price per share (in dollars per share)" } } }, "localname": "TenderOfferPricePerShare", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "pear_TenderOfferSharesAvailableToPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tender Offer, Shares Available To Purchase", "label": "Tender Offer, Shares Available To Purchase", "terseLabel": "Shares to purchase under tender offer (in shares)" } } }, "localname": "TenderOfferSharesAvailableToPurchase", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "pear_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "domainItemType" }, "pear_TheCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Company", "label": "The Company [Member]", "terseLabel": "The Company" } } }, "localname": "TheCompanyMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_TheSponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Sponsor", "label": "The Sponsor [Member]", "terseLabel": "The Sponsor" } } }, "localname": "TheSponsorMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_ThimblePointAcquisitionCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thimble Point Acquisition Corp.", "label": "Thimble Point Acquisition Corp. [Member]", "terseLabel": "Thimble Point Acquisition Corp." } } }, "localname": "ThimblePointAcquisitionCorpMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_ThresholdNumberOfDaysDeterminingLockInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of days determining lock in period.", "label": "Threshold Number Of Days Determining Lock In Period", "terseLabel": "Threshold number of days determining lock in period" } } }, "localname": "ThresholdNumberOfDaysDeterminingLockInPeriod", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_TransactionCostsIncurredInConnectionWithTheIssuanceOfWarrants": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transaction costs incurred in connection with the issuance of warrants.", "label": "Transaction Costs Incurred In Connection With The Issuance Of Warrants", "negatedLabel": "Transaction costs incurred in connection with the issuance of warrants" } } }, "localname": "TransactionCostsIncurredInConnectionWithTheIssuanceOfWarrants", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "pear_TriggerPriceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trigger Price [Axis]", "label": "Trigger Price [Axis]", "terseLabel": "Trigger Price [Axis]" } } }, "localname": "TriggerPriceAxis", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_TriggerPriceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trigger Price [Domain]", "label": "Trigger Price [Domain]", "terseLabel": "Trigger Price [Domain]" } } }, "localname": "TriggerPriceDomain", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_TwoThousandAndTwentyOneConvertibleUnsecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one convertible unsecured promissory note.", "label": "Two Thousand And Twenty One Convertible Unsecured Promissory Note [Member]", "terseLabel": "Two Thousand And Twenty One Convertible Unsecured Promissory Note [Member]" } } }, "localname": "TwoThousandAndTwentyOneConvertibleUnsecuredPromissoryNoteMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "pear_UnderwritersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters member.", "label": "Underwriters [Member]", "terseLabel": "Underwriters [Member]" } } }, "localname": "UnderwritersMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "pear_UnusualOrInfrequentItemsOrBothDeferredPaymentLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unusual Or Infrequent Items, Or Both, Deferred Payment, Liability", "label": "Unusual Or Infrequent Items, Or Both, Deferred Payment, Liability", "terseLabel": "Deferred payment liability" } } }, "localname": "UnusualOrInfrequentItemsOrBothDeferredPaymentLiability", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "pear_UpfrontPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upfront Payment", "label": "Upfront Payment [Member]", "terseLabel": "Upfront Payment" } } }, "localname": "UpfrontPaymentMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "domainItemType" }, "pear_VotingRightsPreferredStockOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting Rights, Preferred Stock Outstanding, Shares", "label": "Voting Rights, Preferred Stock Outstanding, Shares", "terseLabel": "Voting rights, outstanding shares" } } }, "localname": "VotingRightsPreferredStockOutstandingShares", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "pear_WarrantLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Liability, Noncurrent", "label": "Warrant Liability, Noncurrent", "terseLabel": "Warrant liabilities" } } }, "localname": "WarrantLiabilityNoncurrent", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "pear_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liability .", "label": "Warrant Liability [Policy Text Block]", "terseLabel": "Warrant Liabilities" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "pear_WarrantLiabilityPrivatePlacementWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability private placement warrants.", "label": "Warrant Liability Private Placement Warrants", "verboseLabel": "Warrant Liability \u2013 Private Placement Warrants" } } }, "localname": "WarrantLiabilityPrivatePlacementWarrants", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "pear_WarrantLiabilityPublicWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability public warrants.", "label": "Warrant Liability Public Warrants", "terseLabel": "Warrant Liability \u2013 Public Warrants" } } }, "localname": "WarrantLiabilityPublicWarrants", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "pear_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Disclosure.", "label": "Warrants Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "pear_WarrantsExercisableTermFromTheClosingOfIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Exercisable Term From The Closing Of IPO.", "label": "Warrants Exercisable Term From The Closing Of IPO", "terseLabel": "Warrants exercisable term from the closing of IPO" } } }, "localname": "WarrantsExercisableTermFromTheClosingOfIpo", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_WarrantsExercisableTermFromTheDateOfCompletionOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Exercisable Term From The Date Of Completion Of Business Combination.", "label": "Warrants Exercisable Term From The Date Of Completion Of Business Combination", "terseLabel": "Public Warrants exercisable, Terms" } } }, "localname": "WarrantsExercisableTermFromTheDateOfCompletionOfBusinessCombination", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "pear_WarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Line Items]", "label": "Warrants [Line Items]", "terseLabel": "Warrants [Line Items]" } } }, "localname": "WarrantsLineItems", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_WarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Table]", "label": "Warrants [Table]", "terseLabel": "Warrants [Table]" } } }, "localname": "WarrantsTable", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "pear_WorkingCapitalLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loans member.", "label": "Working Capital Loans [Member]", "terseLabel": "Working Capital Loans [Member]" } } }, "localname": "WorkingCapitalLoansMember", "nsuri": "http://www.peartherapeutics.com/20211223", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r61", "r63", "r131", "r132", "r298", "r346" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r297", "r345", "r412", "r415", "r610", "r611", "r612", "r613", "r614", "r615", "r634", "r690", "r693", "r727", "r728" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r297", "r345", "r412", "r415", "r610", "r611", "r612", "r613", "r614", "r615", "r634", "r690", "r693", "r727", "r728" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r213", "r392", "r396", "r637", "r689", "r691" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r213", "r392", "r396", "r637", "r689", "r691" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r297", "r345", "r400", "r412", "r415", "r610", "r611", "r612", "r613", "r614", "r615", "r634", "r690", "r693", "r727", "r728" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r297", "r345", "r400", "r412", "r415", "r610", "r611", "r612", "r613", "r614", "r615", "r634", "r690", "r693", "r727", "r728" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r62", "r63", "r131", "r132", "r298", "r346" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r3", "r136", "r137", "r138", "r140", "r141", "r145", "r146", "r147", "r148", "r150", "r151", "r152", "r153", "r154", "r155", "r175", "r236", "r237", "r457", "r489", "r532", "r536", "r537", "r538", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r3", "r136", "r137", "r138", "r140", "r141", "r145", "r146", "r147", "r148", "r150", "r151", "r152", "r153", "r154", "r155", "r175", "r236", "r237", "r457", "r489", "r532", "r536", "r537", "r538", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r149", "r413" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r149", "r155", "r413" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r214", "r215", "r392", "r397", "r692", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r214", "r215", "r392", "r397", "r692", "r710", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r149", "r155", "r266", "r413", "r602" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r8", "r30", "r218", "r219" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r111" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Accretion and amortization of interest income" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14", "r15", "r48" ], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r662", "r684" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued Royalties", "terseLabel": "Accrued royalties and maintenance" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r256" ], "calculation": { "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r67", "r68", "r69", "r679", "r701", "r705" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r66", "r69", "r77", "r78", "r79", "r136", "r137", "r138", "r514", "r696", "r697", "r744" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r31", "r457", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r136", "r137", "r138", "r454", "r455", "r456", "r536" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r417", "r420", "r460", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r359", "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Class A common stock issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r293", "r359", "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of warrants", "verboseLabel": "Cash Placement Warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r464" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r420", "r446", "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock based compensation expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r539", "r552" ], "calculation": { "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "U.S. Treasury bills" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r89", "r110", "r317", "r576" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r110", "r251", "r252" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible asset" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of office space (in sqft)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r127", "r196", "r205", "r211", "r231", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r510", "r515", "r559", "r597", "r599", "r654", "r675" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r12", "r60", "r127", "r231", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r510", "r515", "r559", "r597", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r540" ], "calculation": { "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r122" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Marketable securities held in Trust Account", "verboseLabel": "Assets held in the Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r223", "r225", "r243", "r661" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Short-term investments", "verboseLabel": "Debt investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r421", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r522", "r524" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r411", "r414" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r411", "r414", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r501" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "verboseLabel": "Percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r39", "r599", "r706", "r707" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r39", "r112" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails_1": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash \u2013 End of period", "periodStartLabel": "Cash \u2013 Beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net Change in Cash" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r17", "r113", "r653" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash and cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r105", "r112", "r118" ], "calculation": { "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r105", "r568" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash with Federal Deposit Insurance Company" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r124", "r127", "r160", "r161", "r166", "r169", "r171", "r179", "r180", "r181", "r231", "r280", "r285", "r286", "r287", "r291", "r292", "r343", "r344", "r348", "r352", "r559", "r732" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]", "verboseLabel": "Stock holders Equity Note [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r369", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]", "verboseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Stock issued, exercise price", "verboseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of securities called by each warrant or right" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of common stock into which the class of warrant or right converted" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r503", "r504", "r507" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "COLLABORATION AND LICENSE AGREEMENTS" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r53", "r265", "r663", "r683" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments (Note 6)", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r262", "r263", "r264", "r272", "r714" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIES", "http://www.peartherapeutics.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total number of shares (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock, Conversion Basis", "terseLabel": "Common stock, Conversion basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r136", "r137", "r536" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10KParenthetical", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10QParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10KParenthetical", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10QParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10KParenthetical", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10QParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r359" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10KParenthetical", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10QParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common stock, Voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r72", "r74", "r75", "r81", "r665", "r686" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r184", "r672" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Risks and Uncertainties", "verboseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r120", "r512" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation, Policy", "verboseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Contract with Customer, Contract Asset, Contract Liability, and Receivable" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r371", "r372", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending\u2014December\u00a031, 2020", "periodStartLabel": "Beginning\u2014January 1, 2020" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Change in transaction price", "verboseLabel": "Amounts invoiced" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r371", "r372", "r393" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenues" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r371", "r372", "r393" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenues" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Fair value of the conversion feature (3)", "verboseLabel": "Convertible Promissory Note" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r343", "r344", "r348" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible preferred stock (as converted to common stock)", "verboseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r85", "r637" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Product Revenue" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r84" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total cost and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Cost and operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEarningsDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative earnings (deficits) for relevant time periods.", "label": "Cumulative Earnings (Deficit)", "verboseLabel": "Cumulative earnings (deficit)" } } }, "localname": "CumulativeEarningsDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r115", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Debt instrument convertible in to private warrants", "verboseLabel": "Converted instrument" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r115", "r117" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued upon conversion (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r115", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Original amount of debt before conversion" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r123", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r311", "r318", "r319", "r321", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "INDEBTEDNESS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r23", "r24", "r126", "r134", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r327", "r328", "r329", "r330", "r579", "r655", "r656", "r673" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r24", "r323", "r656", "r673" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "netLabel": "Note payable to collaboration partner", "terseLabel": "Principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Working Capital Loans, Convertible amount" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r296", "r326" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Debt instrument conversion price per share | $ / shares" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r294", "r327", "r328", "r577", "r579", "r580" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Unsecured promissory note (the \"Promissory Note\"), Face amount", "verboseLabel": "Debt instrument face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r50", "r314", "r577" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r50", "r295" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMeasurementInput": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.", "label": "Debt Instrument, Measurement Input", "terseLabel": "Debt measurement input" } } }, "localname": "DebtInstrumentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r51", "r126", "r134", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r327", "r328", "r329", "r330", "r579" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r51", "r126", "r134", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r320", "r327", "r328", "r329", "r330", "r360", "r363", "r364", "r365", "r576", "r577", "r579", "r580", "r671" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r307", "r576", "r580" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Unamortized discount on note payable" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r307", "r324", "r327", "r328", "r578" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Less: Debt issuance costs and discount at issuance" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Equity issuance costs in accounts payable and accrued expenses" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt fees and expenses" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r43", "r307", "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r58", "r250" ], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r582", "r587" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized.", "label": "Deferred Rent Credit", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r483", "r484" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenues" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r476" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r478" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r483", "r484" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Depreciation" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r481", "r483", "r484" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r483", "r484" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r483", "r484" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accrued expenses and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r477" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r483", "r484" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Contribution cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Percent of employee gross pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer percent match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r110", "r254" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r133", "r518", "r519", "r520", "r521", "r526" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r366", "r670" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Accretion for Class A common stock to redemption amount" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r44", "r130", "r283", "r285", "r286", "r290", "r291", "r292", "r592" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Promissory note \u2014 related party loan" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r82", "r145", "r146", "r148", "r149", "r150", "r157", "r160", "r169", "r170", "r171", "r175", "r176", "r537", "r538", "r666", "r687" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted income (loss) per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r82", "r145", "r146", "r148", "r149", "r150", "r160", "r169", "r170", "r171", "r175", "r176", "r537", "r538", "r666", "r687" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Common Share", "verboseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r172", "r173", "r174", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r471" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r128", "r471", "r492" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r471", "r492" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in deferred tax asset valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r471", "r492" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r471", "r492" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r471", "r492" ], "calculation": { "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Federal and state research and development tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESReconciliationofTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r523" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded debt derivative", "verboseLabel": "Fair value of embedded debt derivative" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation costs, period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Outstanding options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r77", "r78", "r79", "r136", "r137", "r138", "r141", "r151", "r154", "r178", "r235", "r359", "r366", "r454", "r455", "r456", "r488", "r489", "r536", "r569", "r570", "r571", "r572", "r573", "r574", "r696", "r697", "r698", "r744" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of debt" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r110", "r334" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "negatedTerseLabel": "Change in estimated fair value of warrant liabilities", "terseLabel": "Change in estimated fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r540", "r541", "r542", "r551" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions", "verboseLabel": "Schedule Of Quantitative Information Regarding Fair Value Measurements of Promissory Note" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "http://www.peartherapeutics.com/role/FairValueMeasurementsTables", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r540", "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r540", "r557" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities at Fair Value" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r309", "r327", "r328", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r541", "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "verboseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r540", "r541", "r544", "r545", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "verboseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r309", "r401", "r402", "r407", "r409", "r541", "r607" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r309", "r327", "r328", "r401", "r402", "r407", "r409", "r541", "r608" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r309", "r327", "r328", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r541", "r609" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "localname": "FairValueInputsQuantitativeInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "verboseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r546", "r551" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "verboseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r546", "r551" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in the Fair Value of Warrant Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "http://www.peartherapeutics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "verboseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 to level 1", "verboseLabel": "Transfers out of Levels" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r547" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Initial measurement on February 4, 2021", "verboseLabel": "Issuance of warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r309", "r327", "r328", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "verboseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r550", "r553" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r554", "r556" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r226", "r227", "r228", "r229", "r230", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r320", "r357", "r527", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r732", "r733", "r734", "r735", "r736", "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts [Member]" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r110", "r331", "r332" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "(Loss) gain on extinguishment of debt", "terseLabel": "(Loss) gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r416", "r418", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r253", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r258", "r261" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r128", "r472", "r474", "r480", "r490", "r493", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r129", "r153", "r154", "r195", "r470", "r491", "r494", "r688" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r76", "r468", "r469", "r474", "r475", "r479", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current and long-term liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r109", "r635" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenues" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r667" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest and other (expense) income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r104", "r106", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r662", "r684" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "negatedTerseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r88", "r194" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest earned on marketable securities held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r540" ], "calculation": { "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "totalLabel": "Total investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47", "r127", "r206", "r231", "r280", "r281", "r282", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r511", "r515", "r516", "r559", "r597", "r598" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r127", "r231", "r559", "r599", "r658", "r681" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY", "verboseLabel": "Liabilities, convertible preferred stock and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Liabilities Assumed", "terseLabel": "Deferred underwriting fee payable", "verboseLabel": "Recognition of warrant liabilities" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r127", "r231", "r280", "r281", "r282", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r511", "r515", "r516", "r559", "r597", "r598", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement Terms" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r24", "r308", "r325", "r327", "r328", "r656", "r676" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Debt outstanding", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Current portion of long-term debt", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r134", "r277", "r313" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_1": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_2": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r134", "r277", "r313" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r134", "r277", "r313" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_1": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_2": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r134", "r277", "r313" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_1": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r134" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails_2": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Year One" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt\u2014less current maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Purchase commitment amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r51", "r278" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-term Purchase Commitment, Period", "terseLabel": "Purchase commitment period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "verboseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r83" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized loss on marketable securities held in Trust Account" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputConversionPriceMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using price per share at which convertible share can be converted into common stock.", "label": "Measurement Input, Conversion Price [Member]", "terseLabel": "Measurement Input, Conversion Price [Member]" } } }, "localname": "MeasurementInputConversionPriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected life (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Fair value of underlying preferred stock" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r105" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r105" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r105", "r108", "r111" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r70", "r73", "r79", "r80", "r111", "r127", "r140", "r145", "r146", "r148", "r149", "r153", "r154", "r167", "r196", "r204", "r207", "r210", "r212", "r231", "r280", "r281", "r282", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r538", "r559", "r664", "r685" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTerseLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net income (loss)", "verboseLabel": "Allocation of net loss, as adjusted" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r145", "r146", "r148", "r149", "r157", "r158", "r168", "r171", "r196", "r204", "r207", "r210", "r212" ], "calculation": { "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Basic and diluted net loss per common stock" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r159", "r162", "r163", "r164", "r165", "r168", "r171" ], "calculation": { "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r139", "r140", "r141", "r142", "r143", "r144", "r148", "r155", "r175", "r221", "r222", "r232", "r233", "r234", "r235", "r236", "r237", "r279", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r486", "r487", "r488", "r489", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r588", "r638", "r639", "r640", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r740", "r741", "r742", "r743", "r744" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements/Recently Issued Accounting Pronouncements Not Yet Adopted", "verboseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-Cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r115", "r116", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Payment of milestone license in intangibles and accrued expenses" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncatastrophicEventAxis": { "auth_ref": [ "r689" ], "lang": { "en-us": { "role": { "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Axis]", "terseLabel": "Noncatastrophic Event [Axis]" } } }, "localname": "NoncatastrophicEventAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NoncatastrophicEventDomain": { "auth_ref": [ "r689" ], "lang": { "en-us": { "role": { "documentation": "Noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Domain]", "terseLabel": "Noncatastrophic Event [Domain]" } } }, "localname": "NoncatastrophicEventDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r24", "r656", "r676" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "verboseLabel": "Promissory note" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozNotePayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "terseLabel": "Operating and formation costs" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r196", "r204", "r207", "r210", "r212" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r581", "r583" ], "calculation": { "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r581", "r583" ], "calculation": { "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r581", "r583" ], "calculation": { "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r581", "r583" ], "calculation": { "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r581", "r583" ], "calculation": { "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "NATURE OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r135", "r156", "r190", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Description of Organization and Business Operations" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r64", "r65", "r67" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized (loss) gain on short-term investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r71", "r74", "r508", "r509", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Long-Term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expenses):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r48", "r275" ], "calculation": { "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r99" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.", "label": "Payments for Repurchase of Redeemable Convertible Preferred Stock", "negatedTerseLabel": "Repurchase of common and convertible preferred stock, net of issuance costs" } } }, "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "terseLabel": "Payments for underwriting expense" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Payment for extinguishment of debt" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r102" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Deferred financing fees and related debt issuance costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r102" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs", "terseLabel": "Stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r92", "r94", "r224" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r95" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r96" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedLabel": "Investment of cash in Trust Account" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r421", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r343" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, Par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28", "r343" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r28", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r37", "r38" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r9", "r11", "r248", "r249" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail", "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofChangesintheFairValueofWarrantLiabilitiesDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Proceeds From Interest Received" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance of IPO" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r97" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r97" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock, net" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r98" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from PIPE" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r97" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of Private Placement Warrants", "verboseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from sale of equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r92", "r93", "r224" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of short-term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r98" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from promissory note \u2013 related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Proceeds from promissory note \u2013 related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r97", "r449" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenue" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r260", "r715", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r255" ], "calculation": { "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r257", "r599", "r669", "r682" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r257", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r18", "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTTables", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r255" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r25", "r657", "r677" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount": { "auth_ref": [ "r337", "r338", "r339", "r340" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of common shares (regardless of class), limited partnership units (regardless of class), non-preferential membership interests, or any other form of common equity regardless of investee entity legal form.", "label": "Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount", "terseLabel": "Class A common stock subject to possible redemption 27,600,000 and 0 shares at September 30, 2021 (at redemption value of $10 per share) and December 31, 2020, respectively" } } }, "localname": "RedeemableNoncontrollingInterestEquityCommonCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r408", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r591", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transaction amounts of transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r408", "r591", "r592", "r594" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Expense paid to Sponsor" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r408", "r591", "r594", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsScheduleOfQuantitativeInformationRegardingFairValueMeasurementsofPromissoryNoteDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r589", "r590", "r592", "r595", "r596" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED-PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONS", "http://www.peartherapeutics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Principal payments on debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayment of promissory note \u2013 related party", "verboseLabel": "Repayment of promissory note \u2013 related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r465", "r636", "r729" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "LICENSE AGREEMENTS" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r118", "r653", "r678" ], "calculation": { "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails_1": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r7", "r17", "r118" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash - short-term" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r13", "r20", "r118", "r712" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash - long-term" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r708", "r709", "r711", "r713" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Marketable securities held in Trust Account" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r366", "r457", "r599", "r680", "r700", "r705" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r136", "r137", "r138", "r141", "r151", "r154", "r235", "r454", "r455", "r456", "r488", "r489", "r536", "r696", "r698" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "auth_ref": [ "r502", "r505" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Revenue from arrangement" } } }, "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r192", "r193", "r203", "r208", "r209", "r213", "r214", "r216", "r391", "r392", "r637" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r121", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r382", "r395", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "COLLABORATION AND LICENSE AGREEMENTS" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Period of satisfaction" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty and maintenance expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Consideration received on transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock (in shares)", "verboseLabel": "Sale of Stock, Number of Shares Issued in Transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock (in dollars per share)", "verboseLabel": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSChangeinDeferredRevenueDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r51", "r134", "r327", "r329", "r360", "r363", "r364", "r365", "r576", "r577", "r580", "r671" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long Term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSTables", "http://www.peartherapeutics.com/role/INDEBTEDNESSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NETLOSSPERSHARETables", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r160", "r161", "r169", "r171", "r176" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "verboseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r420", "r445", "r459" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r420", "r445", "r459" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Lease Payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r257" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r593", "r594" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/LICENSEAGREEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r17", "r118", "r653", "r678" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r17", "r118", "r653", "r678" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r421", "r448" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r428", "r435", "r437" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r54", "r124", "r179", "r180", "r335", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r352", "r357", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]", "verboseLabel": "Stockholders Equity Note [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r27", "r28", "r29", "r336", "r341", "r342", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule of Subsidiary or Equity Method Investee [Table]", "terseLabel": "Sale of Stock [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]", "terseLabel": "Series D Preferred Stock" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r109" ], "calculation": { "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Restricted stock vested during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant (in shares)", "verboseLabel": "Common stock options available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled and forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted in period (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r430", "r448" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance, options outstanding (in shares)", "periodStartLabel": "Beginning balance, options outstanding (in shares)", "terseLabel": "Outstanding common stock options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance, options outstanding (in dollars per share)", "periodStartLabel": "Beginning balance, options outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r419", "r425" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r421", "r426" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r418", "r444" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Employee [Member]", "terseLabel": "Employee" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Price per share (in dollars per share)", "verboseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r440", "r458" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of vested stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Founder shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Stock issued, purchase price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Founder shares outstanding" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r22", "r659", "r660", "r674" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r119", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Internal-use software" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r27", "r28", "r29", "r124", "r127", "r160", "r161", "r166", "r169", "r171", "r179", "r180", "r181", "r231", "r280", "r285", "r286", "r287", "r291", "r292", "r343", "r344", "r348", "r352", "r359", "r559", "r732" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r57", "r77", "r78", "r79", "r136", "r137", "r138", "r141", "r151", "r154", "r178", "r235", "r359", "r366", "r454", "r455", "r456", "r488", "r489", "r536", "r569", "r570", "r571", "r572", "r573", "r574", "r696", "r697", "r698", "r744" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r136", "r137", "r138", "r178", "r637" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]", "verboseLabel": "Net income" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofCashFlows", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICITParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Granted in period" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued for services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r359", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Gross proceeds", "verboseLabel": "Stock shares issued during the period shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r28", "r29", "r359", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r359", "r366", "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/STOCKBASEDCOMPENSATIONCommonStockOptionsDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r28", "r29", "r359", "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued, Value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r359", "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r57", "r359", "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r28", "r29", "r359", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of preferred and common shares (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r28", "r29", "r359", "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of preferred and common shares", "terseLabel": "Shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r34", "r35", "r127", "r220", "r231", "r559", "r599" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersDeficitEquity", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' (Deficit) Equity", "verboseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r125", "r344", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r366", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "COMMON STOCK" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCK", "http://www.peartherapeutics.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split effected" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r575", "r601" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r575", "r601" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r575", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r575", "r601" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails", "http://www.peartherapeutics.com/role/SubsequentEventsThimbleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r600", "r603" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTS", "http://www.peartherapeutics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CommitmentsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/DescriptionofOrganizationandBusinessOperationsAdditionalInformationDetails", "http://www.peartherapeutics.com/role/NATUREOFBUSINESSOrganizationDetails", "http://www.peartherapeutics.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "verboseLabel": "Accretion of carrying value to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r16", "r336" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]", "terseLabel": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r280", "r285", "r286", "r287", "r291", "r292" ], "calculation": { "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Carrying Value", "verboseLabel": "Convertible preferred stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10K", "http://www.peartherapeutics.com/role/CONSOLIDATEDBALANCESHEETS10Q", "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]", "terseLabel": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Liquidation Preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreferencePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference Per Share", "terseLabel": "Conversion Price/Share (in dollars per share)" } } }, "localname": "TemporaryEquityLiquidationPreferencePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r16", "r336" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Par Value (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r16", "r336" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Temporary Equity, Redemption Price Per Share" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Outstanding (in shares)", "verboseLabel": "Common stock subject to possible redemption" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKDetails", "http://www.peartherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementofChangesinStockholdersEquityThimbleParenthetical", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperationsThimbleParenthetical", "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryofClassACommonStockSubjecttoPossibleRedemptionDetails", "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Series D convertible preferred stock, net of issuance costs of $83" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r16", "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Convertible Preferred Stock" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONVERTIBLEPREFERREDSTOCKTables", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r226", "r227", "r228", "r229", "r230", "r320", "r357", "r527", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r732", "r733", "r734", "r735", "r736", "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsTables", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r56", "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSNovartisDetails", "http://www.peartherapeutics.com/role/COLLABORATIONANDLICENSEAGREEMENTSSandozDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r43" ], "calculation": { "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSFutureMinimumPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualOrInfrequentItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Unusual or Infrequent Item, or Both [Line Items]", "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]" } } }, "localname": "UnusualOrInfrequentItemLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemTable": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Table]", "terseLabel": "Unusual or Infrequent Item, or Both [Table]" } } }, "localname": "UnusualOrInfrequentItemTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/NATUREOFBUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r182", "r183", "r185", "r186", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r478" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INCOMETAXESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock", "verboseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/COMMONSTOCKDetails", "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSLevel3RollForwardDetails", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREAntidilituveSecuritiesDetails", "http://www.peartherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liabilities" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSAssetsandFairValueDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSPerceptiveCreditFacilityDetails", "http://www.peartherapeutics.com/role/INDEBTEDNESSSVBTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Effective expiration date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/FAIRVALUEMEASUREMENTSValuationAssumptionsDetails", "http://www.peartherapeutics.com/role/FairValueMeasurementsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Number of warrants or rights outstanding" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.peartherapeutics.com/role/WarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted average number diluted shares outstanding adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r159", "r171" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/SummaryofSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r157", "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.peartherapeutics.com/role/CondensedConsolidatedStatementsofOperations", "http://www.peartherapeutics.com/role/NETLOSSPERSHAREBasicandDilutedPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.peartherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r462": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r497": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r507": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r517": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r555": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r596": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r603": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r730": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r731": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r732": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r733": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r734": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r735": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r736": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r737": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r738": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r739": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" } }, "version": "2.1" }